I
Ines Maria Vaz Duarte Luis
Researcher at Institut Gustave Roussy
Publications - 33
Citations - 169
Ines Maria Vaz Duarte Luis is an academic researcher from Institut Gustave Roussy. The author has contributed to research in topics: Breast cancer & Medicine. The author has an hindex of 5, co-authored 21 publications receiving 100 citations. Previous affiliations of Ines Maria Vaz Duarte Luis include French Institute of Health and Medical Research & Harvard University.
Papers
More filters
Journal ArticleDOI
Impact of Breast Cancer Treatment on Employment: Results of a Multicenter Prospective Cohort Study (CANTO).
Agnès Dumas,Agnès Dumas,Ines Maria Vaz Duarte Luis,Ines Maria Vaz Duarte Luis,Thomas Bovagnet,Mayssam El Mouhebb,Mayssam El Mouhebb,Antonio Di Meglio,Sandrine Pinto,Cécile Charles,Cécile Charles,Sarah Dauchy,Suzette Delaloge,Patrick Arveux,Charles Coutant,Paul Cottu,A. Lesur,Florence Lerebours,Olivier Tredan,Laurence Vanlemmens,Christelle Levy,Jérôme Lemonnier,Christelle Mesleard,Fabrice Andre,Fabrice Andre,Gwenn Menvielle +25 more
TL;DR: This comprehensive study identifies potentially vulnerable patients with stage I-III breast cancer and warrants supportive interventional strategies to facilitate their RTW.
Journal ArticleDOI
Use and Duration of Chemotherapy in Patients With Metastatic Breast Cancer According to Tumor Subtype and Line of Therapy
Davinia S.E. Seah,Ines Maria Vaz Duarte Luis,Erin Macrae,Jessica Sohl,Georgia Litsas,Eric P. Winer,Nan Lin,Harold J. Burstein +7 more
TL;DR: Among patients with HR(+) and HER2-amplified disease who undergo chemotherapy beyond the third line, substantial rates of prolonged therapies suggest clinical benefit and the role of advanced (greater than third) chemotherapy lines in improving survival of all patients with MBC warrants further study.
Journal ArticleDOI
Randomized phase II study of eribulin mesylate (E) with or without pembrolizumab (P) for hormone receptor-positive (HR+) metastatic breast cancer (MBC).
Sara M. Tolaney,Romualdo Barroso-Sousa,Tanya Keenan,Lorenzo Trippa,Jiani Hu,Ines Maria Vaz Duarte Luis,Gerburg M. Wulf,Laura Spring,Natalie Faye Sinclair,Chelsea Andrews,Jessica Pittenger,Edward T. Richardson,Deborah A. Dillon,Nan Lin,Beth Overmoyer,Ann H. Partridge,Eliezer VanAllen,Elizabeth A. Mittendorf,Eric P. Winer,Ian E. Krop +19 more
TL;DR: Data is reported from the first randomized study comparing E plus P versus E alone in HR+/HER2- MBC, which shows only modest activity in studies of checkpoint inhibitor monotherapy.
Journal ArticleDOI
Body weight and return to work among survivors of early-stage breast cancer
Antonio Di Meglio,Gwenn Menvielle,Agnès Dumas,Arnauld S. Gbenou,Sandrine Pinto,Thomas Bovagnet,Elise Martin,Arlindo R. Ferreira,Laurence Vanlemmens,Olivier Arsene,Mahmoud Ibrahim,Johanna Wassermann,Anne Laure Martin,Jérôme Lemonnier,Lucia Del Mastro,Lee W. Jones,Ann H. Partridge,Jennifer A. Ligibel,Fabrice Andre,Fabrice Andre,Stefan Michiels,Stefan Michiels,Ines Maria Vaz Duarte Luis +22 more
TL;DR: Excess weight may be a barrier to return to work among overweight or obese breast cancer survivors, and weight loss was associated with higher rates ofreturn to work, whereas further weight gain was associatedwith lower likelihood of return toWork.
Journal ArticleDOI
Time trends in the use of adjuvant chemotherapy (CTX) and outcomes in women with T1N0 breast cancer (BC) in the National Comprehensive Cancer Network (NCCN)
Ines Maria Vaz Duarte Luis,Rebecca A. Ottesen,Melissa E. Hughes,Rizvan Mamet,Harold J. Burstein,Stephen B. Edge,Ana M. Gonzalez-Angulo,Sara H. Javid,Beverly Moy,Hope S. Rugo,Richard L. Theriault,Jane C. Weeks,Nan Lin +12 more
TL;DR: Time trends of CTX use and outcomes in women with T1N0 BC treated at NCCN cancer centers are analyzed and more than 50% of patients with HER2+ and HR-2- T1a/b breast cancers received CTX (± trastuzumab) in 2009.